ANTX
ANTX
US0373261058
AN2 Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
38.109.000 54.554.000
30.1%
Operating Income -38.109.000 -54.554.000
30.1%
Pretax Income -35.174.000 -51.321.000
31.5%
Net Income Common Stockholders -35.174.000 -51.321.000
31.5%
-- --
--
-- --
--
ende